DIA dia-b tech limited

11:51, Friday, 23 June 2006 Sydney - Friday - June 23: (RWE Aust...

  1. 56,914 Posts.
    lightbulb Created with Sketch. 289
    11:51, Friday, 23 June 2006

    Sydney - Friday - June 23: (RWE Aust Business News) - Dia-B Tech
    Ltd (ASX:DIA) expects to begin clinical trials of its ISF402
    anti-diabetes compound in the last quarter of 2006 after initial trials
    on animals proved that the compound is effective in lowering blood
    glucose levels.
    Chairman Dr Michael Wooldridge said this milestone now allows the
    company to prepare the appropriate protocols and documentation for
    regulatory approvals to commence Phase 1 human trials after the
    completion of mandatory animal toxicity studies to be completed during
    August.
    "Dia-B is excited with the progress of ISF402 as an oral drug
    that can enhance insulin action to reduce glucose in the blood stream of
    the body, and to potentially benefit type 2 diabetes sufferers world
    wide," he said.

 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.